CO-029,tetraspanin 8,TM4SF3,TM4SF3tspan-8,Transmembrane 4 superfamily member 3tetraspanin-8,TSPAN8,Tspan-8,Tumor-associated antigen CO-029
Human TSPAN8, His Tag (TS8-H52H3) is expressed from human 293 cells (HEK293). It contains AA Lys 110 - Asn 205 (Accession # P19075-1).
Predicted N-terminus: His
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 12.9 kDa. The protein migrates as 14 kDa and 17-19 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human TSPAN8, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Tspan8 is 1 of the 33 mammalian members of the tetraspanin family, composed of transmembrane proteins that organize laterally, together or with other membrane partners such as integrins, to form ‘tetraspanin webs’. These platforms signal within cells to regulate many cellular processes: adhesion, migration, invasion or survival Tspan8 has been implicated in many types of cancer.Overexpression was reported in glioma and colorectal, esophageal, hepatic, gastric and pancreatic carcinoma. Tspan8 exerts a pro-invasive function by controlling cell–cell and cell–matrix interactions through its association with membrane partners such as α6β4 integrin-protein kinase C (PKC)-activated, E-cadherin, EpCAM, claudin-7 and CD44. Moreover, Tspan8 may be a promising new therapeutic target, as Tspan8-specific antibodies were shown to reduce cell motility, block tumor angiogenesis in vivo.